Search

Your search keyword '"Pomeroy, Emily J."' showing total 9 results
Start Over Author "Pomeroy, Emily J." Publication Year Range Last 3 years
9 results on '"Pomeroy, Emily J."'

1. Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies

Author

Skeate, Joseph G., Pomeroy, Emily J., Slipek, Nicholas J., Jones, Bryan J., Wick, Bryce J., Chang, Jae-Woong, Lahr, Walker S., Stelljes, Erin M., Patrinostro, Xiaobai, Barnes, Blake, Zarecki, Trevor, Krueger, Joshua B., Bridge, Jacob E., Robbins, Gabrielle M., McCormick, Madeline D., Leerar, John R., Wenzel, Kari T., Hornberger, Kathlyn M., Walker, Kirsti, Smedley, Dalton, Largaespada, David A., Otto, Neil, Webber, Beau R., and Moriarity, Branden S.

Published
2024
Full Text
View/download PDF

2. Supplementary Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

Author

Smeester, Branden A., primary, Draper, Garrett M., primary, Slipek, Nicholas J., primary, Larsson, Alex T., primary, Stratton, Natalie, primary, Pomeroy, Emily J., primary, Becklin, Kelsie L., primary, Yamamoto, Kenta, primary, Williams, Kyle B., primary, Laoharawee, Kanut, primary, Peterson, Joseph J., primary, Abrahante, Juan E., primary, Rathe, Susan K., primary, Mills, Lauren J., primary, Crosby, Margaret R., primary, Hudson, Wendy A., primary, Rahrmann, Eric P., primary, Largaespada, David A., primary, and Moriarity, Branden S., primary

Published
2023
Full Text
View/download PDF

3. Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

Author

Smeester, Branden A., primary, Draper, Garrett M., primary, Slipek, Nicholas J., primary, Larsson, Alex T., primary, Stratton, Natalie, primary, Pomeroy, Emily J., primary, Becklin, Kelsie L., primary, Yamamoto, Kenta, primary, Williams, Kyle B., primary, Laoharawee, Kanut, primary, Peterson, Joseph J., primary, Abrahante, Juan E., primary, Rathe, Susan K., primary, Mills, Lauren J., primary, Crosby, Margaret R., primary, Hudson, Wendy A., primary, Rahrmann, Eric P., primary, Largaespada, David A., primary, and Moriarity, Branden S., primary

Published
2023
Full Text
View/download PDF

4. Table S2 from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

Author

Smeester, Branden A., primary, Draper, Garrett M., primary, Slipek, Nicholas J., primary, Larsson, Alex T., primary, Stratton, Natalie, primary, Pomeroy, Emily J., primary, Becklin, Kelsie L., primary, Yamamoto, Kenta, primary, Williams, Kyle B., primary, Laoharawee, Kanut, primary, Peterson, Joseph J., primary, Abrahante, Juan E., primary, Rathe, Susan K., primary, Mills, Lauren J., primary, Crosby, Margaret R., primary, Hudson, Wendy A., primary, Rahrmann, Eric P., primary, Largaespada, David A., primary, and Moriarity, Branden S., primary

Published
2023
Full Text
View/download PDF

5. Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production

Author

Dahlvang, James D., primary, Dick, Jenna K., additional, Sangala, Jules A., additional, Kennedy, Philippa R., additional, Pomeroy, Emily J., additional, Snyder, Kristin M., additional, Moushon, Juliette M., additional, Thefaine, Claire E., additional, Wu, Jianming, additional, Hamilton, Sara E., additional, Felices, Martin, additional, Miller, Jeffrey S., additional, Walcheck, Bruce, additional, Webber, Beau R., additional, Moriarity, Branden S., additional, and Hart, Geoffrey T., additional

Published
2023
Full Text
View/download PDF

6. Ablation of SYK kinase from primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production

Author

Dahlvang, James D., primary, Dick, Jenna K., additional, Sangala, Jules A., additional, Pomeroy, Emily J., additional, Snyder, Kristin M., additional, Moushon, Juliette M., additional, Thefaine, Claire E., additional, Wu, Jianming, additional, Hamilton, Sara E., additional, Felices, Martin, additional, Miller, Jeffrey S., additional, Walcheck, Bruce, additional, Webber, Beau R., additional, Moriarity, Branden S., additional, and Hart, Geoffrey T., additional

Published
2022
Full Text
View/download PDF

8. Multiplex Prime Editing and PASSIGE TMfor Non-Viral Generation of an Allogeneic CAR-T Cell Product

Author

Pomeroy, Emily J, Anzalone, Andrew V, Podracky, Christopher J, Bloch, Noah B, Chang, Reyna, Dwivedi, Arika A, Laoharawee, Kanut, Wilhelm, Alan J, Waterman, David P, Tedeschi, Justin G, Arvindam, Upasana Sunil, Macari, Elizabeth R, Gori, Jennifer L, and Duffield, Jeremy S

Abstract

While CAR-T cell therapy represents a major advance in personalized immunotherapy, the autologous nature of commercially available CAR-T products have delayed its broad application beyond a subset of hematological malignancies. In particular, manufacturing autologous CAR-T therapies is costly and time-consuming, and success relies on the fitness of a patient's cells. An allogeneic off-the-shelf CAR-T product could overcome these cell quality and quantity issues and could be accessed on-demand. However, a successful allogeneic CAR-T product will require multiplex gene knockout in addition to stable CAR integration to prevent graft-versus-host disease (GvHD) and graft rejection by the patient's immune system.

Published
2023
Full Text
View/download PDF

9. Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing.

Author

Wang M, Krueger JB, Gilkey AK, Stelljes EM, Kluesner MG, Pomeroy EJ, Skeate JG, Slipek NJ, Lahr WS, Vázquez PNC, Zhao Y, Eaton EJ, Laoharawee K, Webber BR, and Moriarity BS

Abstract

Natural killer (NK) cells' unique ability to kill transformed cells expressing stress ligands or lacking major histocompatibility complexes (MHC) has prompted their development for immunotherapy. However, NK cells have demonstrated only moderate responses against cancer in clinical trials and likely require advanced genome engineering to reach their full potential as a cancer therapeutic. Multiplex genome editing with CRISPR/Cas9 base editors (BE) has been used to enhance T cell function and has already entered clinical trials but has not been reported in human NK cells. Here, we report the first application of BE in primary NK cells to achieve both loss-of-function and gain-of-function mutations. We observed highly efficient single and multiplex base editing, resulting in significantly enhanced NK cell function. Next, we combined multiplex BE with non-viral TcBuster transposon-based integration to generate IL-15 armored CD19 CAR-NK cells with significantly improved functionality in a highly suppressive model of Burkitt's lymphoma both in vitro and in vivo . The use of concomitant non-viral transposon engineering with multiplex base editing thus represents a highly versatile and efficient platform to generate CAR-NK products for cell-based immunotherapy and affords the flexibility to tailor multiple gene edits to maximize the effectiveness of the therapy for the cancer type being treated., Competing Interests: Conflict of interest statement M.W., E.J.P., M.G.K., B.S.M. and B.R.W. have filed patents covering the methods and approaches outlined in this work.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results